Enhancement of oxaliplatin-induced cell apoptosis and tumor suppression by 3-methyladenine in colon cancer

Tan,Shisheng; Peng,Xingchen; Peng,Wen; Zhao,Yinglan; Wei,Yuquan

doi:10.3892/ol.2015.2996

Enhancement of oxaliplatin-induced cell apoptosis and tumor suppression by 3-methyladenine in colon cancer

Authors:
- Shisheng Tan
- Xingchen Peng
- Wen Peng
- Yinglan Zhao
- Yuquan Wei
View Affiliations

Affiliations: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, P.R. China
Published online on: February 27, 2015 https://doi.org/10.3892/ol.2015.2996
Pages: 2056-2062
Copyright: © Tan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oxaliplatin (OX) has been widely used in adjuvant and palliative treatments of advanced colon cancer; however, cancer cells ultimately become resistant in the majority of cases. Therefore, the development of a novel strategy to overcome this resistance is important for the effective treatment of colon cancer. Cell autophagy reduces the sensitivity of cancer cells to therapeutic reagents in various types of human cancer; therefore, the present study used murine CT26 colon carcinoma cells to explore whether inhibition of autophagy by 3‑methyladenine (3‑MA) is able to enhance OX‑induced apoptosis in vitro and OX‑suppressed tumor growth in vivo. CT26 cells were treated with 3‑MA, OX, or 3‑MA plus OX, and the autophagy, apoptosis and proliferation of the CT26 cells was investigated. Additionally, the therapeutic efficiency of the combination of 3‑MA and OX treatment was evaluated in vivo by determining the survival time of the tumor‑bearing mice and, thus, tumor growth rate. The treatment of CT26 cells in vitro with OX alone increased autophagy as well as apoptosis, whereas treatment with 3‑MA plus OX markedly inhibited OX‑induced autophagy, but increased OX‑induced cell apoptosis. Furthermore, the combination of OX and 3‑MA treatment significantly suppressed tumor growth in vivo and prolonged mouse survival time when compared with OX treatment alone. Similarly, 3‑MA increased OX‑induced cell apoptosis and decreased autophagy in xenograft tumor tissues. Thus, the administration of 3‑MA may increase tumor cell sensitivity to OX by reducing its autophagic effects and enhancing its apoptotic effects. Data obtained in the present study indicates that the clinical combination of an autophagy inhibitor with OX may increase the therapeutic effect of OX and improve the clinical outcome of patients with colon cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. Feb 4–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
3	Dahan L, Sadok A, Formento JL, Seitz JF and Kovacic H: Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol. 158:610–620. 2009. View Article : Google Scholar : PubMed/NCBI
4	Bleiberg H: Oxaliplatin (L-OHP): a new reality in colorectal cancer. Brit J Cancer. (Suppl 4). 1–3. 1998. View Article : Google Scholar : PubMed/NCBI
5	Alcindor T and Beauger N: Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 18:18–25. 2011. View Article : Google Scholar : PubMed/NCBI
6	Howells LM, Sale S, Sriramareddy SN, et al: Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo. Int J Cancer. 129:476–486. 2011. View Article : Google Scholar : PubMed/NCBI
7	Klionsky DJ and Emr SD: Autophagy as a regulated pathway of cellular degradation. Science. 290:1717–1721. 2000. View Article : Google Scholar : PubMed/NCBI
8	White E: Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 12:401–410. 2012. View Article : Google Scholar : PubMed/NCBI
9	Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
10	Chen S, Rehman SK, Zhang W, Wen A, Yao L and Zhang J: Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta. 1806:220–229. 2010.PubMed/NCBI
11	Bijnsdorp IV, Peters GJ, Temmink OH, Fukushima M and Kruyt FA: Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int J Cancer. 126:2457–2468. 2010.PubMed/NCBI
12	Li J, Hou N, Faried A, Tsutsumi S, Takeuchi T and Kuwano H: Inhibition of autophagy by 3-MA enhances the effect of 5-FU-induced apoptosis in colon cancer cells. Ann Surg Oncol. 16:761–771. 2009. View Article : Google Scholar : PubMed/NCBI
13	Shi Y, Tang B, Yu PW, et al: Autophagy protects against oxaliplatin-induced cell death via ER stress and ROS in Caco-2 cells. PloS One. 7:e510762012. View Article : Google Scholar : PubMed/NCBI
14	Xu Y, Yu H, Qin H, et al: Inhibition of autophagy enhances cisplatin cytotoxicity through endoplasmic reticulum stress in human cervical cancer cells. Cancer Lett. 314:232–243. 2012. View Article : Google Scholar : PubMed/NCBI
15	Sasaki K, Tsuno NH, Sunami E, et al: Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer. 10:3702010. View Article : Google Scholar : PubMed/NCBI
16	Shi W, Tang Q, Chen X, et al: Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer. J Mol Med (Berl). 87:493–506. 2009. View Article : Google Scholar : PubMed/NCBI
17	Amaravadi RK, Yu D, Lum JJ, et al: Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest. 117:326–336. 2007. View Article : Google Scholar : PubMed/NCBI
18	Romano S, D'Angelillo A, Pacelli R, et al: Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells. Cell Death Differ. 17:145–157. 2010. View Article : Google Scholar : PubMed/NCBI
19	de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 18:2938–2947. 2000.PubMed/NCBI
20	André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 27:3109–3116. 2009. View Article : Google Scholar : PubMed/NCBI
21	Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 25:2198–2204. 2007. View Article : Google Scholar : PubMed/NCBI
22	He G, Wang Y, Pang X and Zhang B: Inhibition of autophagy induced by TSA sensitizes colon cancer cell to radiation. Tumour Biol. 35:1003–1011. 2014. View Article : Google Scholar : PubMed/NCBI
23	Giatromanolaki A, Koukourakis MI, Harris AL, Polychronidis A, Gatter KC and Sivridis E: Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomas. J Clin Pathol. 63:867–872. 2010. View Article : Google Scholar : PubMed/NCBI
24	Giatromanolaki A, Koukourakis MI, Koutsopoulos AV, Harris AL, Gatter KC and Sivridis E: Autophagy and hypoxia in colonic adenomas related to aggressive features. Colorectal Dis. 15:e223–e230. 2013. View Article : Google Scholar : PubMed/NCBI
25	Koukourakis MI, Giatromanolaki A, Sivridis E, Pitiakoudis M, Gatter KC and Harris AL: Beclin 1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia. Brit J Cancer. 103:1209–1214. 2010. View Article : Google Scholar : PubMed/NCBI